Serum levels of YKL-40 from normal healthy individuals, patients at high risk for developing ovarian cancer, and ovarian cancer patients were assessed in a study by Dupont et al. which demonstrated that higher levels of YKL-40 were observed in stage I and stage II patients. Here, CHI3L1 is linked to ovarian cancer.